Syncom Formulations Quarterly Results
Syncom Formulations quarterly results. In Mar 2026, Syncom Formulations (SYNCOMF) reported revenue ₹150 Cr and net profit ₹25 Cr — revenue -3.8% YoY. For annual financials, live price and key ratios, visit SYNCOMF share price screener.
SYNCOMF Quarterly Results — Revenue, Profit & EPS Highlights
Syncom Formulations latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review SYNCOMF P/E ratio to evaluate earnings-based valuation against sector peers.
- Revenue of ₹150 Cr in Mar 2026 (+12.8% vs Jun 2026, -3.8% vs Mar 2025)
- Net Profit of ₹25 Cr in Mar 2026 (+0.0% vs Jun 2026, +38.9% vs Mar 2025)
- EBITDA of ₹37 Cr in Mar 2026 (+8.8% vs Jun 2026)
- Operating Margin of 16.0% in Mar 2026 (-5.0pp vs Jun 2026)
- Earnings Per Share of ₹0.27 in Mar 2026 (+3.8% vs Jun 2026)
Syncom Formulations Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SYNCOMF quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 150 | 133 | 127 | 156 | 123 | 12.8% | -3.8% |
| Net Profit (₹ Cr) | 25 | 25 | 17 | 18 | 16 | - | - |
| EBITDA (₹ Cr) | 37 | 34 | 24 | 25 | 22 | - | - |
| EPS (₹) | 0.27 | 0.26 | 0.18 | 0.19 | 0.21 | - | - |
| Operating Margin (%) | 16.0% | 21.0% | 15.0% | 12.0% | 14.0% | - | - |
SYNCOMF Share Price Trend — 1-Year Movement Across Quarterly Results
Syncom Formulations 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check SYNCOMF market value to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SYNCOMF vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Syncom Formulations latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores